Anja J. Rueten-Budde

Anja J. Rueten-Budde

Auto-generated profile, based on publicly available information

Anja J. Rueten-Budde

Mathematical Institute, Leiden University, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SMSkander Tahar Mulder
Skander Tahar Mulder
AOAmir-Houshang Omidvari
Amir-Houshang Omidvari
ARAnja J Rueten-Budde
Anja J Rueten-Budde
PHPei-Hua Huang
Pei-Hua Huang
KKKihun Kim
Kihun Kim
R.P.M. Steegers-TheunissenR.P.M. Steegers-Theunissen
R.P.M. Steegers-Theunissen
A digital twin (DT), originally defined as a virtual representation of a physical asset, system, or process, is a new concept in health care. A DT in health care is not a single technology but a domain-adapted multimodal modeling approach incorporating the acquisition, management, analysis, prediction, and interpretation of data, aiming to improve medical decision-making. However, there are many challenges and barriers that must be overcome before a DT can be used in health care. In this viewpoint paper, we build on the current literature, address these challenges, and describe a dynamic DT in health care for optimizing individual patient health care journeys, specifically for women at risk for cardiovascular complications in the preconception and pregnancy periods and across the life course. We describe how we can commit multiple domains to developing this DT. With our cross-domain definition of the DT, we aim to define future goals, trade-offs, and methods that will guide the development of the dynamic DT and implementation strategies in health care.

1 December 2018 in Surgical Oncology
Verified
Journal Article
Open access
ARA.J. Rueten-Budde
A.J. Rueten-Budde
VPV.M. van Praag
V.M. van Praag
Michiel A. J. van de SandeMichiel A. J. van de Sande
Michiel A. J. van de Sande
MFM. Fiocco
M. Fiocco
LJLee Jeys
Lee Jeys
RHRick L. Haas
Rick L. Haas
There is increasing interest in personalized prediction of disease progression for soft tissue sarcoma patients. Currently, available prediction models are limited to predictions from time of surgery or diagnosis. This study updates predictions of overall survival at different times during follow-up by using the concept of dynamic prediction. Information from 2232 patients with high-grade extremity soft tissue sarcoma, who underwent surgery at 14 specialized sarcoma centers, was used to develop a dynamic prediction model. The model provides updated 5-year survival probabilities from different prediction time points during follow-up. Baseline covariates as well as time-dependent covariates, such as status of local recurrence and distant metastases, were included in the model. In addition, the effect of covariates over time was investigated and modelled accordingly in the prediction model. Surgical margin and tumor histology show a significant time-varying effect on overall survival. The effect of margin is strongest shortly after surgery and diminishes slightly over time. Development of local recurrence and distant metastases during follow-up have a strong effect on overall survival and updated predictions must account for their occurrence. The presence of time-varying effects, as well as the effect of local recurrence and distant metastases on survival, suggest the importance of updating predictions during follow-up. This newly developed dynamic prediction model which updates survival probabilities over time can be used to make better individualized treatment decisions based on a dynamic assessment of a patient's prognosis.

17 July 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
MMM.J.L. Mastboom
M.J.L. Mastboom
ESEric Lodewijk Staals
Eric Lodewijk Staals
FVFloortje Verspoor
Floortje Verspoor
ARA.J. Rueten-Budde
A.J. Rueten-Budde
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
OGon behalf of the Tenosynovial Giant Cell Tumors (TGCT) Study Group
on behalf of the Tenosynovial Giant Cell Tumors (TGCT) Study Group
Update: This article was updated on April 9, 2020, because of a previous error. On page 1309, in the list of Tenosynovial Giant Cell Tumors (TGCT) Study Group members, the contributor name that had read “M. Wook Joo” should have read “M.W. Joo.” An erratum has been published: J Bone Joint Surg Am. 2020 May 20;102(10):e49. Background: Localized-type tenosynovial giant cell tumor (TGCT) is a rare, neoplastic disease with only limited data supporting treatment protocols. We describe treatment protocols and evaluate their oncological outcome, complications, and functional results in a large multicenter cohort of patients. A secondary study aim was to identify factors associated with local recurrence after surgical treatment. Methods: Patients with histologically proven localized TGCT of a large joint were included if they had been treated between 1990 and 2017 in 1 of 31 tertiary sarcoma centers. Of 941 patients with localized TGCT, 62% were female. The median age at initial treatment was 39 years, and the median duration of follow-up was 34 months. Sixty-seven percent of the tumors affected the knee, and the primary treatment at the tertiary center was 1-stage open resection in 73% of the patients. Proposed factors for predicting a first local recurrence after treatment in the tertiary center were tested in a univariate analysis, and those that demonstrated significance were subsequently included in a multivariate analysis. Results: The localized TGCT recurred in 12% of all cases, with local-recurrence-free rates at 3, 5, and 10 years of 88%, 83%, and 79%, respectively. The strongest factor for predicting recurrent disease was a prior recurrence (p < 0.001). Surgical treatment decreased pain and swelling in 71% and 85% of the patients, respectively, and such treatment was associated with complications in 4% of the patients. Univariate and multivariate analyses of the patients who had not undergone therapy previously yielded positive associations between local recurrence and a tumor size of ≥5 cm versus <5 cm (hazard ratio [HR] = 2.50; 95% confidence interval [CI] = 1.32 to 4.74; p = 0.005). Arthroscopy (versus open surgery) was significantly associated with tumor recurrence in the univariate analysis (p = 0.04) but not in the multivariate analysis (p = 0.056). Conclusions: Factors associated with recurrence after resection of localized-type TGCT were larger tumor size and initial treatment with arthroscopy. Relatively low complication rates and good functional outcomes warrant an open approach with complete resection when possible to reduce recurrence rates in high-risk patients. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

4 August 2020 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
ESE.M. Schutgens
E.M. Schutgens
PPPiero Picci
Piero Picci
DBD. Baumhoer
D. Baumhoer
RPR. Pollock
R. Pollock
Judith V.M.G. BovéeJudith V.M.G. Bovée
Judith V.M.G. Bovée
AGAdamantinoma Research Group
Adamantinoma Research Group
Background: Osteofibrous dysplasia-like adamantinoma (OFD-AD) and classic adamantinoma (AD) are rare, neoplastic diseases with only limited data supporting current treatment protocols. We believe that our retrospective multicenter cohort study is the largest analysis of patients with adamantinoma to date. The primary purpose of this study was to describe the disease characteristics and evaluate the oncological outcomes. The secondary purpose was to identify risk factors for local recurrence after surgical treatment and propose treatment guidelines. Methods: Three hundred and eighteen confirmed cases of OFD-AD and AD for which primary treatment was carried out between 1985 and 2015 were submitted by 22 tertiary bone tumor centers. Proposed clinical risk factors for local recurrence such as size, type, and margins were analyzed using univariable and multivariate Cox regression analysis. Results: Of the 318 cases, 128 were OFD-AD and 190 were AD. The mean age at diagnosis was 17 years (median, 14.5 years) for OFD-AD and 32 years (median, 28 years) for AD; 53% of the patients were female. The mean tumor size in the OFD-AD and AD groups combined was 7.8 cm, measured histologically. Sixteen percent of the patients sustained a pathological fracture prior to treatment. Local recurrence was recorded in 22% of the OFD-AD cases and 24% of the AD cases. None of the recurrences in the OFD-AD group progressed to AD. Metastatic disease was found in 18% of the AD cases and fatal disease, in 11% of the AD cases. No metastatic or fatal disease was reported in the OFD-AD group. Multivariate Cox regression analysis demonstrated that uncontaminated resection margins (hazard ratio [HR] = 0.164, 95% confidence interval [CI] = 0.092 to 0.290, p < 0.001), pathological fracture (HR = 1.968, 95% CI = 1.076 to 3.600, p = 0.028), and sex (female versus male: HR = 0.535, 95% CI = 0.300 to 0.952, p = 0.033) impacted the risk of local recurrence. Conclusions: OFD-AD and AD are parts of a disease spectrum but should be regarded as different entities. Our results support reclassification of OFD-AD into the intermediate locally aggressive category, based on the local recurrence rate of 22% and absence of metastases. In our study, metastatic disease was restricted to the AD group (an 18% rate). We advocate wide resection with uncontaminated margins including bone and involved periosteum for both OFD-AD and AD. Level of Evidence: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

17 December 2020 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ARAnja J. Rueten‐Budde
Anja J. Rueten‐Budde
VPVeroniek M. van Praag
Veroniek M. van Praag
MSMichiel A. J. van de Sande
Michiel A. J. van de Sande
MFMarta Fiocco
Marta Fiocco
PGPERSARC Study Group
PERSARC Study Group
Background and Objectives: A dynamic prediction model for patients with soft tissue sarcoma of the extremities was previously developed to predict updated overall survival probabilities throughout patient follow‐up. This study updates and externally validates the dynamic model.Methods: Data from 3826 patients with high‐grade extremity soft tissue sarcoma, treated surgically with curative intent were used to update the dynamic PERsonalised SARcoma Care (PERSARC) model. Patients were added to the model development cohort and grade was included in the model. External validation was performed with data from 1111 patients treated at a single tertiary center.Results: Calibration plots show good model calibration. Dynamic C‐indices suggest that the model can discriminate between high‐ and low‐risk patients. The dynamic C‐indices at 0, 1, 2, 3, 4, and 5 years after surgery were equal to 0.697, 0.790, 0.822, 0.818, 0.812, and 0.827, respectively.Conclusion: Results from the external validation show that the dynamic PERSARC model is reliable in predicting the probability of surviving an additional 5 years from a specific prediction time point during follow‐up. The model combines patient‐, treatment‐specific and time‐dependent variables such as local recurrence and distant metastasis to provide accurate survival predictions throughout follow‐up and is available through the PERSARC app.

18 October 2018 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
ARAnja J. Rueten‐Budde
Anja J. Rueten‐Budde
HPHein Putter
Hein Putter
MFMarta Fiocco
Marta Fiocco
Survival analysis is used in the medical field to identify the effect of predictive variables on time to a specific event. Generally, not all variation of survival time can be explained by observed covariates. The effect of unobserved variables on the risk of a patient is called frailty. In multicenter studies, the unobserved center effect can induce frailty on its patients, which can lead to selection bias over time when ignored. For this reason, it is common practice in multicenter studies to include a random frailty term modeling center effect. In a more complex event structure, more than one type of event is possible. Independent frailty variables representing center effect can be incorporated in the model for each competing event. However, in the medical context, events representing disease progression are likely related and correlation is missed when assuming frailties to be independent. In this work, an additive gamma frailty model to account for correlation between frailties in a competing risks model is proposed, to model frailties at center level. Correlation indicates a common center effect on both events and measures how closely the risks are related. Estimation of the model using the expectation‐maximization algorithm is illustrated. The model is applied to a data set from a multicenter clinical trial on breast cancer from the European Organisation for Research and Treatment of Cancer (EORTC trial 10854). Hospitals are compared by employing empirical Bayes estimates methodology together with corresponding confidence intervals.